Abstract:e13508 Background: Murine double minute-2 (MDM2) has increasing clinic relevance as preclinical and early clinical evidences have showed that the MDM2 inhibitors are promising alternative treatments for patients with MDM2-amplified (-amp) and TP53-wild-type (-WT) tumors by preventing TP53 protein degradation. However, exploration into genomic landscape of MDM2/TP53 across various solid tumors in Chinese patients is still limited. Methods: Formalin-fixed, paraffin-embedded (FFPE) tumor samples were collected from 10010 Chinese patients with solid tumors and subjected to a clinical-grade next-generation sequencing (NGS)-based 450 gene panel testing carried out by a College of American Pathologists (CAP) accredited and Clinical Laboratory Improvement Amendments (CLIA) certified laboratory. Genomic alterations (GAs) including single base substitutions, short and long insertion/deletions (Indels), copy number variations, gene fusions, and rearrangements were analyzed. Tumor mutational burden (TMB) was measured by a NGS algorithm. Results: Amplification of MDM2 occurred in 3.3% of Chinese patients. MDM2-amp was detected most frequently in soft tissue sarcoma (STS, 11.4 %), melanoma (10.3 %) and osteosarcoma (6.3 %). Notably, MDM2-amp was revealed to be mutually exclusive with TP53-mut in most tumor types other than esophageal carcinoma (93.9 %), head and neck carcinoma (68.4%) and ovarian carcinoma (50 %). Tumors with highest frequencies of MDM2-amp/ TP53-WT were melanoma (100%), osteosarcoma (100%) and urothelial carcinoma (100 %). The most common co-altered genes accompanied with MDM2-amp were FRS2 (84%), CDK4 (38%), EGFR (26%), TP53 (17%) and GLI1 (14%). 82.8% patients who had one or more co-alterations potentially targetable with either FDA-approved or investigational agent. Moreover, TMB of MDM2-amp tumors were significantly lower than that of MDM2-WT and MDM2-mutation (-mut) tumors (median TMB: 3.1 vs. 4.6 vs. 10.8, p < 0.001 respectively). Conclusions: MDM2 amplification was found in 3.3% of 10010 Chinese cancer patients, 83.4% of whom harbored wild-type TP53 that were potentially responsive to MDM2 inhibitors. In addition, 82.8% of the patients with MDM2-amp harbored genomic co-alterations and were potentially therapy targetable. This study provided insights into identifying patients who might potentially benefit from anti-MDM2 therapies.

1715P the Landscape of SMAD4 Alteration in Chinese Solid Tumor Patients

P1.03-02 Analysis of SMAD4 Aberrations in Chinese Patients with Non-Small-Cell Lung Cancer

SMAD4 mutation correlates with poor prognosis in non-small cell lung cancer

SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer.

Comprehensive Profiling of MDM2/TP53 Genomic Aberration in Chinese Patients with Diverse Malignancies.

<i>SMAD4</i> Gene Mutations Are Associated with Poor Prognosis in Pancreatic Cancer

Additional File 4: of SMAD4 and NF1 Mutations As Potential Biomarkers for Poor Prognosis to Cetuximab-Based Therapy in Chinese Metastatic Colorectal Cancer Patients

Genetic Alterations of SMYD4 in Solid Tumors Using Integrative Multi-Platform Analysis

Clinical features and prognostic biomarkers in patients with SMARCA4-mutated non-small cell lung cancer

SMAD4 and NF1 Mutations As Potential Biomarkers for Poor Prognosis to Cetuximab-Based Therapy in Chinese Metastatic Colorectal Cancer Patients.

Distinct expression and prognostic value of members of SMAD family in non-small cell lung cancer

Integrated multi-omics characterization of SMAD4 mutant colorectal cancer

Molecular Analyses of the 15q and 18q SMAD Genes in Pancreatic Cancer.

The landscape of ATM alteration in Chinese solid tumor patients.

Pan-Cancer analysis of the mutation frequency of genes in TGF-beta pathway.

Prognostic Value of SMAD4 in Resectable Pancreatic Cancer

Comprehensive Genomic Profiling of Sarcomas in Chinese Population.

Landscape of somatic alterations in large-scale solid tumors from an Asian population

Smad4 Loss In Colorectal Cancer: Correlation With Recurrence, Chemoresistance, And Immune Infiltrate.

23P Genomic Profiling of Gene Aberrations in 323 Chinese NSCLC Patients

P2.03-35 Non-Small-Cell Lung Cancer with SMO Gene Variants of Uncertain Significance Share Distinct Molecular Features